These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 37943967)

  • 1. Retained Gastric Contents After Adequate Fasting Associated with GLP-1 Receptor Agonist Use: A Report of 3 Cases.
    Kittner SL; Talbott AL; Vishneski SR; Narbaiza J; Shields JS
    JBJS Case Connect; 2023 Oct; 13(4):. PubMed ID: 37943967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Particulate Gastric Contents in Patients Prescribed Glucagon-Like Peptide 1 Receptor Agonists After Appropriate Perioperative Fasting: A Report of 2 Cases.
    Wilson PR; Bridges KH; Wilson SH
    A A Pract; 2023 Aug; 17(8):e01712. PubMed ID: 37616174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency of GLP-1 receptor agonists use in diabetic patients diagnosed with delayed gastric emptying and their demographic profile.
    Kalas MA; Dang TQ; Galura G; Alvarado L; Dwivedi AK; Deoker A; McCallum R
    J Investig Med; 2023 Jan; 71(1):11-16. PubMed ID: 36198436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exenatide Delays Gastric Emptying in Patients with Type 2 Diabetes Mellitus but not in Those with Gastroparetic Conditions.
    Beti C; Stratmann B; Bokman G; Dreier J; Hauber M; Lee-Barkey YH; Fischer M; Knabbe C; Tschoepe D
    Horm Metab Res; 2019 Apr; 51(4):267-273. PubMed ID: 30690693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report.
    Gulak MA; Murphy P
    Can J Anaesth; 2023 Aug; 70(8):1397-1400. PubMed ID: 37280458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity.
    Maselli DB; Camilleri M
    Adv Exp Med Biol; 2021; 1307():171-192. PubMed ID: 32077010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study.
    Takeshita Y; Kita Y; Tanaka T; Goto H; Nakano Y; Teramura C; Enyama Y; Takamura T;
    J Diabetes Investig; 2022 Jun; 13(6):965-974. PubMed ID: 35034428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.
    Kuwata H; Yabe D; Murotani K; Fujiwara Y; Haraguchi T; Kubota S; Kubota-Okamoto S; Usui R; Ishitobi M; Yamazaki Y; Hamamoto Y; Kurose T; Seino Y; Yamada Y; Seino Y
    J Diabetes Investig; 2021 Dec; 12(12):2162-2171. PubMed ID: 34022121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.
    Urva S; Coskun T; Loghin C; Cui X; Beebe E; O'Farrell L; Briere DA; Benson C; Nauck MA; Haupt A
    Diabetes Obes Metab; 2020 Oct; 22(10):1886-1891. PubMed ID: 32519795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
    Nauck MA; Niedereichholz U; Ettler R; Holst JJ; Orskov C; Ritzel R; Schmiegel WH
    Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central glucagon like peptide-1 delays solid gastric emptying via central CRF and peripheral sympathetic pathway in rats.
    Nakade Y; Tsukamoto K; Pappas TN; Takahashi T
    Brain Res; 2006 Sep; 1111(1):117-21. PubMed ID: 16884700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans.
    Meier JJ; Gethmann A; Götze O; Gallwitz B; Holst JJ; Schmidt WE; Nauck MA
    Diabetologia; 2006 Mar; 49(3):452-8. PubMed ID: 16447057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.
    Meier JJ; Gallwitz B; Salmen S; Goetze O; Holst JJ; Schmidt WE; Nauck MA
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2719-25. PubMed ID: 12788879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
    Nauck MA; Quast DR; Wefers J; Meier JJ
    Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
    Guo XH
    Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose kinetics: an update and novel insights into its regulation by glucagon and GLP-1.
    Gastaldelli A; Gaggini M; DeFronzo R
    Curr Opin Clin Nutr Metab Care; 2017 Jul; 20(4):300-309. PubMed ID: 28463898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report.
    Klein SR; Hobai IA
    Can J Anaesth; 2023 Aug; 70(8):1394-1396. PubMed ID: 36977934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.
    Meier JJ; Gethmann A; Nauck MA; Götze O; Schmitz F; Deacon CF; Gallwitz B; Schmidt WE; Holst JJ
    Am J Physiol Endocrinol Metab; 2006 Jun; 290(6):E1118-23. PubMed ID: 16403774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
    Østergaard L; Frandsen CS; Madsbad S
    Expert Rev Clin Pharmacol; 2016; 9(2):241-65. PubMed ID: 26573176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
    Willms B; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Nauck MA
    J Clin Endocrinol Metab; 1996 Jan; 81(1):327-32. PubMed ID: 8550773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.